A detailed history of Twinbeech Capital LP transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Twinbeech Capital LP holds 58,208 shares of BEAM stock, worth $1.69 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
58,208
Holding current value
$1.69 Million
% of portfolio
0.03%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$22.57 - $33.14 $1.31 Million - $1.93 Million
58,208 New
58,208 $1.43 Million
Q1 2024

May 15, 2024

BUY
$23.46 - $45.07 $812,677 - $1.56 Million
34,641 New
34,641 $1.14 Million
Q2 2023

Aug 14, 2023

SELL
$29.32 - $35.99 $3.37 Million - $4.14 Million
-114,933 Reduced 89.95%
12,846 $410,000
Q1 2023

May 15, 2023

BUY
$30.15 - $48.79 $3.85 Million - $6.23 Million
127,779 New
127,779 $3.91 Million
Q3 2022

Nov 14, 2022

BUY
$39.79 - $70.31 $2 Million - $3.53 Million
50,216 New
50,216 $2.39 Million

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $2.04B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Twinbeech Capital LP Portfolio

Follow Twinbeech Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Twinbeech Capital LP with notifications on news.